Syngoi Technologies is a new company incorporated in February 2021 and is the result of an initial seed investment by the venture capital fund dedicated to Health and Life Sciences Columbus Venture Partners (http://columbusvp.com).
Syngoi is dedicated to the production of synthetic DNA on demand, as a contract development and manufacturing organisation (CDMO), for biotech companies developing and commercialising therapeutic strategies in Advanced Therapies.
Our initial objective is to establish a pilot plant, production under GMP standard accredited by the regulatory agency (initially EMA), to cover DNA needs for clinical studies.